GlassScriptPhysician profile
Jill M Galley
NPI 1417391087
$6,971.94
in general payments reported to CMS, 2019-2025
35 companies · $1,757 in 2025
The $1,757 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,256 · 2022: $1,129 · 2023: $1,041 · 2024: $1,788 · 2025: $1,757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,586.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,166.72 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,030.22 | 2021-2025 | |
| Lilly USA, LLC | $706.69 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $586.49 | 2021-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $532.55 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $397.33 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $294.76 | 2024-2025 | Relistor |
| Glaxosmithkline, LLC. | $271.96 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Shield Therapeutics INC | $233.53 | 2023-2025 | Accrufer |
| Gilead Sciences, INC. | $178.70 | 2022-2025 | |
| Viatris Specialty LLC | $168.31 | 2025 | Yupelri |
| Exact Sciences Corporation | $152.24 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.61 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $140.44 | 2022 | |
| Lundbeck LLC | $121.03 | 2023-2025 | Rexulti |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $120.05 | 2023-2025 | Proclaim, Axium, Eterna |
| Scilex Pharmaceuticals INC. | $108.48 | 2021-2025 | |
| Astellas Pharma US INC | $101.18 | 2024-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $99.29 | 2024-2025 | Caplyta |
| Daiichi Sankyo INC. | $55.79 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $44.92 | 2025 | Voquezna |
| Hologic Sales and Service, LLC | $37.69 | 2021-2024 | Aptima |
| Roche Diagnostics Corporation | $34.21 | 2021 | |
| Eisai INC. | $32.45 | 2021 | |
| Optinose US, INC. | $31.67 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $27.32 | 2021 | |
| Axsome Therapeutics, INC. | $23.10 | 2025 | Auvelity |
| Ultragenyx Pharmaceutical INC. | $23.08 | 2021 | |
| Uswm, LLC | $19.45 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.21 | 2024 | Eliquis |
| Cumberland Pharmaceuticals, INC. | $15.43 | 2024 | Kristalose |
| Teva Pharmaceuticals USA, INC. | $14.92 | 2022 | |
| Horizon Therapeutics Plc | $13.62 | 2021 | |
| Dexcom, INC. | $13.50 | 2023 | Dexcom G6 Transmitter |
| Vivaquant INC, Dba Rhythm Express | $13.00 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Galley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.